Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22655985 | 0.87 | SMN1; SMN2 (0.44) | GAAALDH1A1GFERSMN1; SMN2CYP4F2 | |
| SCHEMBL6161648 | 0.83 | MAPK1 (0.42) | GAAALDH1A1SMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL8915526 | 0.83 | GAA (0.40) | GAAALDH1A1GFERSMN1; SMN2CYP4F2 | |
| SCHEMBL1457038 | 0.81 | SMN1; SMN2 (0.50) | GAAALDH1A1SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL7714693 | 0.81 | GAA (0.44) | GAAALDH1A1GFERSMN1; SMN2CYP4F2 | |
| SCHEMBL7708882 | 0.79 | ALDH1A1 (0.45) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL30765545 | 0.79 | F7 (0.40) | GAAALDH1A1GFERSMN1; SMN2CYP4F2 | |
| SCHEMBL7245085 | 0.78 | CA2 (0.36) | ALDH1A1HDAC1HDAC6 | |
| SCHEMBL9985451 | 0.78 | SMN1; SMN2 (0.56) | GAAALDH1A1GFERSMN1; SMN2CYP4F2 | |
| SCHEMBL30739832 | 0.78 | AKR1B1 (0.39) | GAAALDH1A1SMN1; SMN2HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| EP-4263541-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116710451-A | Novel aryl-pyrido-pyrimidin-one derivatives | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022129260-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021202900-A1 | 1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-6852761-B2 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040138275-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-20030236231-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6660885-B2 | Serine protease inhibitor | PHARMACIA CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-02-28 | — | — | US | disclosed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | QDPR, P2RY1, REN | GAA 3127/4885ALDH1A1 377/4885GFER 3184/4885 |
| US-20030236231-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | GAA 1195/4885ALDH1A1 2669/4885GFER 592/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | GAA 4023/4885ALDH1A1 3527/4885GFER 1613/4885 |
| US-20210315869-A1 | COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR | MC2R, SLC10A1, SLC10A2 | GAA 2375/4885ALDH1A1 2544/4885GFER 3448/4885 |
| US-20040138275-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | GAA 1195/4885ALDH1A1 2669/4885GFER 592/4885 |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | GAA 1195/4885ALDH1A1 2669/4885GFER 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.